Cost of illness in patients with post-treatment Lyme disease syndrome in Belgium
暂无分享,去创建一个
[1] N. Speybroeck,et al. Lyme borreliosis in Belgium: a cost-of-illness analysis , 2022, BMC Public Health.
[2] N. Speybroeck,et al. Non-specific symptoms and post-treatment Lyme disease syndrome in patients with Lyme borreliosis: a prospective cohort study in Belgium (2016–2020) , 2022, BMC Infectious Diseases.
[3] V. Soti,et al. Post-Treatment Lyme Disease Syndrome: Need for Diagnosis and Treatment , 2021, Cureus.
[4] B. Kullberg,et al. Lyme borreliosis: diagnosis and management , 2020, BMJ.
[5] Alison W. Rebman,et al. Post-treatment Lyme Disease as a Model for Persistent Symptoms in Lyme Disease , 2020, Frontiers in Medicine.
[6] N. Speybroeck,et al. Combining primary care surveillance and a meta-analysis to estimate the incidence of the clinical manifestations of Lyme borreliosis in Belgium, 2015-2017. , 2019, Ticks and tick-borne diseases.
[7] B. Sander,et al. The economic burden of Lyme disease and the cost-effectiveness of Lyme disease interventions: A scoping review , 2019, PloS one.
[8] P. Freeman,et al. Precision Medicine: The Role of the MSIDS Model in Defining, Diagnosing, and Treating Chronic Lyme Disease/Post Treatment Lyme Disease Syndrome and Other Chronic Illness: Part 2 , 2018, Healthcare.
[9] T. Lancet. Introducing EU-wide surveillance of Lyme neuroborreliosis , 2018, The Lancet.
[10] Alison W. Rebman,et al. The Clinical, Symptom, and Quality-of-Life Characterization of a Well-Defined Group of Patients with Posttreatment Lyme Disease Syndrome , 2017, Front. Med..
[11] C. C. van den Wijngaard,et al. The cost of Lyme borreliosis , 2017, European journal of public health.
[12] J. Halperin,et al. Unorthodox alternative therapies marketed to treat Lyme disease. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[13] D. Norris,et al. Epidemiology and cost of hospital care for Lyme borreliosis in Germany: lessons from a health care utilization database analysis. , 2015, Ticks and tick-borne diseases.
[14] R. Sykes,et al. An estimate of Lyme borreliosis incidence in Western Europe† , 2016, Journal of public health.
[15] C. Perronne. Lyme and associated tick-borne diseases: global challenges in the context of a public health threat , 2014, Front. Cell. Infect. Microbiol..
[16] Ather Ali,et al. Experiences of patients identifying with chronic Lyme disease in the healthcare system: a qualitative study , 2014, BMC Family Practice.
[17] Michelle A. Mathiason,et al. Functional outcomes in patients with Borrelia burgdorferi reinfection. , 2014, Ticks and tick-borne diseases.
[18] L. Johnson,et al. Borrelia burgdorferi aggrecanase activity: more evidence for persistent infection in Lyme disease , 2013, Front. Cell. Infect. Microbiol..
[19] J. Coburn,et al. Illuminating the roles of the Borrelia burgdorferi adhesins. , 2013, Trends in microbiology.
[20] K. Berndtson. Review of evidence for immune evasion and persistent infection in Lyme disease , 2013, International journal of general medicine.
[21] G. Wormser,et al. Increased IFNα activity and differential antibody response in patients with a history of Lyme disease and persistent cognitive deficits , 2013, Journal of Neuroimmunology.
[22] T. Mach,et al. Lyme disease: review , 2012, Archives of medical science : AMS.
[23] N. Bossuyt,et al. Incidence and management of presumption of Lyme borreliosis in Belgium: recent data from the sentinel network of general practitioners , 2012, European Journal of Clinical Microbiology & Infectious Diseases.
[24] M. Neteler,et al. Lyme borreliosis in Europe. , 2011, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
[25] J. Ernerudh,et al. Neuroborreliosis--an epidemiological, clinical and healthcare cost study from an endemic area in the south-east of Sweden. , 2010, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[26] E. Shapiro,et al. Implications of gender in chronic Lyme disease. , 2009, Journal of women's health.
[27] E. Single. Why we should still estimate the costs of substance abuse even if we needn't pay undue attention to the bottom line. , 2009, Drug and alcohol review.
[28] C. Varcoe,et al. Expanding Economic Costing in Health Care: Values, Gender and Diversity , 2004 .
[29] P. Cooper,et al. THE ACCURACY OF SELF-REPORTED HEALTHCARE RESOURCE UTILIZATION IN HEALTH ECONOMIC STUDIES , 2002, International Journal of Technology Assessment in Health Care.
[30] S. Wilson. Methods for the economic evaluation of health care programmes , 1987 .
[31] T. Hodgson,et al. The economic costs of the health effects of smoking, 1984. , 1986, The Milbank quarterly.
[32] C. Smithers. REPORT ON CONGRESS , 1972 .
[33] A. Steere,et al. Lyme borreliosis , 2016, Nature Reviews Disease Primers.
[34] Franziska Wulf,et al. Methods For The Economic Evaluation Of Health Care Programmes , 2016 .
[35] J. Caulkins,et al. How Cost-of-Illness Studies Can be Made More Useful for Illicit Drug Policy Analysis , 2006, Applied health economics and health policy.
[36] Thomas E Novotny,et al. US Department of Health and Human Services: a need for global health leadership in preparedness and health diplomacy. , 2006, American journal of public health.